Ekspresja receptorów folitropiny w gruczolakach przysadki — marker agresywności guza?

Abstract

Introduction: In our earlier study, we found that pituitary adenomas, like other human tumours, express ectopically follicle stimulating hormone receptors (FSHR) in intratumoural blood vessels endothelia and/or tumoural cells. The aim of the present paper was to provide more detailed data on FSHR expression in different subtypes of pituitary adenomas and to evaluate its possible role as a prognostic and/ or predictive biomarker in these tumours. Material and methods: Forty two pituitary adenomas, surgically removed, were immunostained with antibodies against the pituitary hormones, antigen Ki-67 and 1-190 fragment of FSHR. Results: The positive FSHR immunostaining was found in blood vessels endothelia of 88% of adenomas and in tumoural cells of 40% adenomas. In tumoural cells, the incidence of at least moderate FSHR immunostaining is significantly higher in invasive tumours (68%) compared to non-invasive (12%) ones, and higher (albeit not statistically significantly) in invasive-proliferating adenomas (Ki-67 > 3%, grade 2b) compared to invasive but non-proliferating (Ki-67 < 3%, grade 2a) ones. Conclusions:The present study confirms that pituitary adenomas ectopically express FSHR in intratumoural blood vessels endothelia and tumoural cells. Moreover, the expression in tumoural cells is prevalent in invasive and proliferating adenomas vs. non-invasive and non-proliferating tumours. (Endokrynol Pol 2014; 65 (6): 469-471)

TMT-based quantitative proteomics revealed follicle-stimulating hormone (FSH)-related molecular characterizations for potentially prognostic assessment and personalized treatment of FSH-positive non-functional pituitary adenomas

“…Study found that FSHR in tumor cells was overexpressed in aggressive PAs compared to non-aggressive PAs [26]. In this study, Western blot analysis revealed that FSHR was significantly upregulated in FSH-positive relative to negative NFPAs ( p < 0.05) (Fig.…”

“…It is necessary to stratify such type of PA patients, reveal their invasive and aggressive mechanisms, and discover the effective biomarkers so as to provide an effective prediction, prognosis, targeted therapy, and personalized treatment strategy. It was reported that FSHR expression in PAs was a marker of aggressiveness [26], and FSHR must bind with FSH to exert their biological roles. Moreover, FSH-positive expressed NFPAs were one of NFPA subtypes [20, 33].…”

“…Moreover, analysis of FSHR expressions among different subtypes of PAs found that the incidence of FSHR expression was significantly higher in aggressive PAs (68%) than in non-aggressive PAs (12%). Thus, FSHR is considered as a marker of aggressiveness of PAs [26]. It is well-known that that FSH exerts its biological roles through binding to FSHR [27–29].…”

Extragonadal FSHR Expression and Function—Is It Real?

“…Endothelial cells of the vessels present in normal-appearing tissues at a distance >10 mm outside the tumors or normal prostate were FSHR-negative (26). In subsequent studies, endothelial FSHR expression was shown in thyroid and neuroendocrine tumors (35, 37, 40). Several groups suggested that the FSHR observed in TVECs and cancer cells is functional (24–26, 70–72).…”

Ekspresja receptorów hormonu dojrzewania pęcherzyków w naczyniach wewnątrzguzowych i komórkach nowotworowych — udział w progresji guzów i perspektywy zastosowania w diagnozie i terapii raka

“…In pituitary adenomas FSHR expression in tumoral cells is prevalent in invasive and proliferating tumours [22]. Thus, the immunostaining of FSHR could play a supplementary role in the histopathological examination.…”